■ Santen Pharmaceutical and Glaukos Corporation said Santen’s US subsidiary, Santen Inc., has entered into a multiyear agreement whereby Glaukos will become the exclusive distributor of the MicroShunt solely in the US market. The MicroShunt is a novel, minimally invasive, ab-externo surgical device being developed for POAG. It is being studied in an FDA pivotal trial for IOP reduction in patients with POAG where IOP is uncontrolled with maximum tolerated medical therapy or where the progression of the disease warrants surgery. Following anticipated completion of the premarket approval submission in 2019, Santen intends to seek US premarket approval and, if approval is granted, launch of the product in the United States in 2020.